le mardi 24 juillet 2018, à 05:10. Posté
par Desmond
Would you like a receipt? http://ecosistemapolitico.com/ai-medicuskz-97e6.pdf keruen-medicus.kz
Drugmaker Retrophin Inc said it offered to buy therest of Transcept Pharmaceuticals shares it does not already ownfor $4 per share, valuing Transcept at about $75 million.Retrophin's offer represents an 11 percent premium toTranscept's closing share price of $3.59 on the Nasdaq onWednesday.